



# COVID-19 VACCINE UPDATES WEBINAR - MARCH

March 31, 2021 Hosted by the Washington Department of Health

## Before We Start...

- All participants will be muted for the presentation.
- You may ask questions using the Q&A box, and questions will be answered at the end of the presentation.
- Continuing education is available for nurses, medical assistants, and pharmacists attending the webinar or watching the recording. If you're watching in a group setting and wish to claim CE credit, please make sure you register for the webinar as an individual and complete the evaluation separately.
- You can find a copy of the slides and more information on our webinar page here:
  - <u>www.doh.wa.gov/YouandYourFamily/Immunization/ImmunizationNews/ImmunizationTraining/COVID19VaccineUpdatesWebinarMarch</u>

### Presenters

Ed Marcuse, MD, MPH, FPIDS

Emeritus Professor, Pediatrics
University of Washington

John Dunn, MD, MPH, FAAP

Medical Director of Preventive Care

Kaiser Permanente

# Continuing Education Disclosure

- The planners and speakers of this activity have no relevant financial relationships with any commercial interests pertaining to this activity.
- Information about obtaining CEs will be available at the end of this webinar.

### Continuing Education

- This continuing nursing education activity was approved by the Montana Nurses
   Association, an accredited approver with distinction by the American Nurses
   Credentialing Center's Commission on Accreditation. Upon successful
   completion of this activity, 1.0 contact hours will be awarded.
- This program has been granted prior approval by the American Association of Medical assistants (AAMA) for 1.0 administrative continuing education unit.
- This training was approved by the Washington State Pharmacy Quality
  Assurance Commission (PQAC) for pharmacist education. Upon successful
  completion of this activity, 1.0 credit hour of continuing education will be
  awarded.


# CURRENT AND UPCOMING COVID-19 VACCINES SAFETY AND EFFECTIVENESS DATA

DR. MARCUSE

## **OUTLINE**


- 1. COVID-19 Vaccine Development
- 2. Terminology & US Authorization Process
- 2. mRNA Vaccines: Safety & Efficacy
- 3. Viral Vector & Protein Vaccines
- 4. Variants
- 5. Unknowns

### COVID-19 VACCINE DEVELOPMENT WORLDWIDE




Source: NY Times Vaccine Tracker 3-25-2021


#### **PFIZER**




#### **JANSSEN - JOHNSON & JOHNSON**




#### **MODERNA**



#### **ASTRAZENECA**




#### GAMALEYA SPUTNIK V




#### **SINOVAX**



#### SINOPHARM & BEIJING INSTITUTE



#### **BHARAT BIOTECH COXAVIN**



# VACCINE RISK, SAFETY, EFFICACY & EFFECTIVENESS

### **Vaccine Risk:**

Expected local & systemic reactions

Adverse events (AE): Non-serious & Serious (SAE\*)

- Initial temporal association, analysis required to determine causality

### Vaccine Safety:

Relative, not absolute: consider in the context of disease risk

- Clinical trials vs post-distribution reports

### Vaccine Efficacy & Effectiveness:

Infection, mild, moderate & severe disease; hospitalization, death

Efficacy against variants; symptomatic & asymptomatic reinfection

\*SAE: hospitalization, life-threatening, persistent disability, death

### FEDERAL VACCINE ADVISORY COMMITTEES

VRBPAC FDA Vaccines & Related Biologic Products Advisory Committee

Licensing & authorization of vaccines, biologicals, drugs

ACIP CDC Advisory Committee on Immunization Practices

Recommendations for the use of FDA-approved vaccines

Members: diverse expertise, vetted for COI, independent, defined terms

Meetings: public, agenda & presentations posted online

## WESTERN STATES VACCINE SAFETY REVIEW GROUP (WSSRG)

CA, NV, OR & WA Governors appointed WSSRG to conduct independent review of vaccine safety, efficacy, review process & recommendations

Members: 11 from CA, 2 each from NV, OR, WA; 9 are former/present members ACIP, VRBPAC, NVAC Meetings: at request of state health depts, governors; reports to governors published online

# BIOLOGICAL LICENSE APPLICATION (BLA) EMERGENCY USE AUTHORIZATION (EUA)

#### **BLA**

Usual licensing process

Requires ≥ 6 mos follow-up data\*

FDA approves as safe & effective

#### **EUA**


Allows distribution or off-label emergency use

FDA finds the benefits outweigh the risks


\*AE associated with licensed US vaccines occurred within 8 weeks of vaccine administration

# CONTINUING PUBLIC HEALTH EMERGENCY COVID-19 PANDEMIC

CASES reported CDC 1/22/2020 – 3/27/2021




**DEATHS** reported CDC 1/22/2020 – 3/27/2021




https://covid.cdc.gov/covid-data-tracker/#datatracker-home

# US COVID-19 7-DAY CASE RATE PER 100,000 (3/28/2021)



## **mRNA VACCINES**




Source: https://www.fda.gov/media/144583/download

## **mRNA VACCINES**

- mRNA human vaccine new, 1990s technology Ebola, Zika, rabies, CMV
- Relatively easy to produce in large quantities, no need for eggs
- mRNA vaccines do NOT contain SARS-CoV-2 virus, cannot cause disease
- mRNA inherently unstable, breaks down rapidly
- Enters the immune cell's cytoplasm, not the nucleus, not incorporated into cell's DNA
- mRNA instructs cell to make the S protein which is displayed on the cell's surface, stimulating humoral and cellular immune responses


# mrna vaccine effectiveness – mayo clinic system




# mrna vaccine effectiveness – Health Care Workers

University of Texas Southwest NEJM 3/21/2021

B Actual and Predicted Positive SARS-CoV-2 Tests



### **US VACCINE SAFETY SYSTEM**




**VAERS:** Vaccine Adverse Event Reporting System

**VSD:** Vaccine Safety Datalink, formerly Large Linked Database

V-SAFE: Vaccine Healthchecker

### VAERS & V-SAFE REPORTS: PFIZER vs MODERNA VACCINES

12/14/2020 - 1/13/2021




A. Pfizer-BioNTech COVID-19 vaccine, dose 1 (N = 749,735)

■ Injection site pain■ Fatigue■ Headache■ Myalgia■ Chills

MMWR 2/19/2021: Vol 70:1-2

### VAERS & V-SAFE REPORTS: PFIZER DOSE #1 vs #2

A. Pfizer-BioNTech COVID-19 vaccine, dose 1 (N = 749,735)



Days since vaccination


MMWR 2/19/2021: Vol 70:1-2

# V-safe pregnancy registry outcomes of interest in COVID-19 vaccinated pregnant women as of February 18, 2021\*

	Background	V-safe pregnancy
Outcomes	rates"	registry overall
Pregnancy outcome		
Miscarriage (<20 weeks)	26%	15% <sup>†</sup>
Stillbirth (≥ 20 weeks)	0.6%	1%
Pregnancy complications		
Gestational diabetes	7-14%	10%
Preeclampsia or gestational hypertension <sup>5</sup>	10-15%	15%
Eclampsia	0.27%	0%
Intrauterine growth restriction	3-7%	1%
Neonatal		
Preterm birth	10.1%	10%
Congenital anomalies <sup>‡</sup>	3%	4%
Small for gestational age <sup>^</sup>	3-7%	4%
Neonatal death	0.38%	0%

<sup>\*</sup> Sources listed on slide 33; † 93% of these were pregnancy losses <13 weeks of age; § Pre-eclampsia or gestational hypertension diagnosed during pregnancy and/or during delivery; ‡ Congenital anomalies (overall) diagnosed after delivery only; ^ Birthweight below the 10th percentile for gestational age and sex using INTERGROWTH-21st Century growth standards

## VIRAL VECTOR COVID-19 VACCINES



### Janssen - Johnson & Johnson

Non-replicating adenovirus 26, used in Ebola vaccine 1 dose EUA approved; 2nd dose at 57 days under study Refrigerator-stable 3 months

Effectiveness varies among strains:

US 72%, Latin America 66%, South Africa 57%


Overall: 66% effective against *moderate-severe* disease 85% effective against severe-critical disease

ACIP & WSVSRG analyses concluded the Janssen vaccine's efficacy is comparable to the Pfizer and Moderna vaccines

## JANSSEN VACCINE: ANTIBODY RESPONSES


Neutralizing

Spike Protein Binding




Source: Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19

## JANSSEN VACCINE: CELLULAR RESPONSES



Source: Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19


# JANSSEN VACCINE: CLINICAL TRIAL EFFICACY BY NUMBER OF SYMPTOMS




Source: Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19

## JANSSEN VACCINE: CLINICAL TRIAL EFFICACY

**Similar** efficacy for across age, sex, race, and ethnicity categories, and those with underlying medical conditions at ≥14 days post-vaccination



### JANSSEN VACCINE: CLINICAL TRIAL – SYSTEMIC & LOCAL AES BY AGE



Source: https://emergency.cdc.gov/coca/calls/2021/callinfo\_030221.asp

# SUMMARY: EFFECTIVENESS PFIZER, MODERNA & JANSSEN VACCINES

- No trials compared efficacy between vaccines in the same study at the same time
  - All Phase 3 trials differed by calendar time and geography
  - Vaccines were tested against different circulating variants and in settings with different background incidence
- All authorized COVID-19 vaccines demonstrated efficacy (range 65 to 95%) against symptomatic lab-confirmed COVID-19
- All authorized COVID-19 vaccines demonstrated high efficacy (≥89%) against COVID-19 severe enough to require hospitalization
- In the vaccine trials, no participants who received a COVID-19 vaccine died from COVID-19
  - The Moderna and Janssen trials each had COVID-19 deaths in the placebo arm

Source: CDC COCO Call 3-3-2021

## **VIRAL VECTOR COVID-19 VACCINES**

# AstraZeneca/Oxford

Non-replicating chimpanzee adenovirus

2 doses, 4 weeks apart, refrigerator-stable

67% effective after 2 doses vs symptomatic disease

Booster effect increased if doses spaced by 12 wks or if lower dose used for dose 1

Effectiveness varies among strains:


Effectiveness vs B.1.351 decreased vs <u>all</u> disease; effectiveness against <u>severe</u> disease TBD

Distributed in Europe, South Africa, Canada

### Data complexities:

Multiple clinical trials; different antigen doses; different spacing of doses #1 & #2; now trials with AZ for dose #1, other vaccines for dose #2

Figure 3: Kaplan-Meyer plot of ChAdOx-1 nCoV19 against all-severity symptomatic Covid-19 illness following two doses versus placebo.




doi: https://doi.org/10.1101/2021.02.10.21251247

## VIRAL VECTOR COVID-19 VACCINES


## Sputnik V

Non-replicating human adenovirus vectors AD 26 dose #1 AD 5 dose #2 Refrigerator-stable A vector is a virus that lacks a gene responsible for reproduction and is used to transport genetic material from another virus that is being vaccinated against into a cell.

The vector does not pose any hazard to the body. The vaccine is based on an adenoviral vector which normally causes acute respiratory viral infections




Vector with a gene coding S protein of coronavirus gets into a cell



The body synthesizes S protein, in response, the production of immunity begins

Repeated vaccination takes place in 21 days



The vaccine based on another adenovirus vector unknown to the body boosts the immune response and provides for long-lasting immunity


### PROTEIN COVID-19 VACCINE

## Novavax & Serum Institute of India

- Insect baculovirus contain DNA code for S protein used to infect moth cells
- Matrix M 1 adjuvant (saponin)\*
- 2 doses, 3 weeks apart, refrigerator-stable
- Overall efficacy UK 96.4%, South Africa 55%
  - Against severe disease UK & SA: 100%

### Others:

Medicago (GSK); ZF2001 (ZVSW China); Soberna (IFV-Cuba); COVAXX (United Biomedical)








<sup>\*</sup>https://www.sciencedirect.com/science/article/pii/S0264410X16001961?via%3Dihub


# **INACTIVATED VIRUS COVID-19 VACCINES**



Sinopharm (China)
Sinovac (China)
Sinopharm-Wuhan (China)
Bharat Biotech (India)


- Various source viruses
- Various methods of viral inactivation

# **SARS-CoV-2 S PROTEIN & VARIANTS**



### SARS-CoV-2 S PROTEIN & VARIANTS

### **CORONAVIRUS GENOME**



- Many variants: D614G, B.1.1.7 (UK), B.1.351 (SA),
   P.1 (Brazil), B.1.427 & B.1.429 (CA), others
- Vaccine-induced antibody neutralization varies by strain, relation to efficacy unclear
- CD8+ T-cell responses should recognize variants
- Vaccine efficacy varies between strains
- Vaccines likely protect against severe disease
- Vaccine-induced immunity exceeds immunity provided by infection with prior strains
- Variants do not affect results of diagnostic tests

# 8.1.1.7

### **SARS-CoV-2 VARIANTS**

B.1.1.7 (UK)

More transmissible, ~50% Increased virulence – 1.7% increase in death rate Vaccines effective

B.1.351 (South Africa)

More transmissible


Uncertain if virulence changed

Decreased neutralization by vaccine antibody

Decreased overall efficacy of current vaccines


Vaccines protect against severe disease, death

## SARS-CoV-2 VARIANTS CIRCULATING IN US 1/31 -2/27/2021



Collection date, week ending, biweekly


### VARIANTS OF CONCERN US 3-28-2021



https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html

### **SARS-CoV-2 VARIANTS**


Reduced neutralization activity of vaccine sera relative to wildtype/dominant strain, by study (n=22)



# Vaccine efficacy or effectiveness (VE) against variants

Vaccine	Study type	VE
Pfizer	Post-licensure	<ul> <li>86% in UK (predominate B.1.1.7 circulation)*</li> <li>94% in Israel (up to 80% of cases from B.1.1.7)</li> </ul>
Janssen	Pre-licensure	<ul> <li>74% in U.S.</li> <li>66% in Brazil</li> <li>52% in S. Africa</li> </ul> 73-82% for severe/critical disease in each country
Novavax	Pre-licensure Pre-licensure	<ul> <li>96% against non-B.1.1.7 in UK</li> <li>86% against B.1.1.7 in UK</li> <li>60% in S. Africa (93% of cases from B.1.351)</li> </ul>
AstraZeneca	Pre-licensure Pre-licensure	<ul> <li>84% against non-B.1.1.7 in UK</li> <li>75% against B.1.1.7 in UK</li> <li>10% against B.1.351 in South Africa</li> </ul>

### VACCINES vs VARIANTS: THE TORTOISE & THE HARE



https://tomaspueyo.substack.com/p/variants-v-vaccines?

### **COVID-19 VACCINES UNKNOWNS**

- Comparative efficacy of mRNA, viral vector vaccines, protein & inactivated vaccines
  - No head-to-head comparison studies on same populations at same time
- Effectiveness of 1 vs 2 doses of 2-dose vaccines
- Duration of immunity
- Relative importance of cellular vs humoral immunity
- Effect on Multisystem Inflammatory Syndrome in Children (MISC)
- Effectiveness & safety in children <12 years</li>

### **RESOURCES**

CDC

https://www.cdc.gov/coronavirus/2019-ncov/index.html https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html

WA State DOH

https://www.doh.wa.gov/Emergencies/COVID19/DataDashboard

NY Times

https://www.nytimes.com/interactive/2020/science/coronavaccine-tracker.html

Washington Post

https://www.washingtonpost.com/graphics/2020/health/covid-vaccine-states-distribution-doses/

UW Dept of Global Health

https://globalhealth.washington.edu/subscribe

# VACCINE RECOMMENDATION UPDATES VACCINE HESITANCY

DR. DUNN

### Obtaining Continuing Education

- Continuing education is available for nurses, medical assistants, and pharmacists.
- Successful completion of this continuing education activity includes the following:
  - Attending the entire live webinar or watching the webinar recording
  - Completing the evaluation available after the webinar or webinar recording
  - NEW: On the evaluation, please check Yes if you're interested in CEs and please specify which type of CE you wish to obtain
  - CE certificates will be automatically sent via email within a week after evaluation completion
- Expiration date is 1/26/22
- If you have any questions about CEs, email Trang Kuss at <a href="mailto:trang.kuss@doh.wa.gov">trang.kuss@doh.wa.gov</a>

Questions?



To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov.